Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1976 1
1979 5
1985 3
1986 6
1987 3
1988 2
1989 6
1990 2
1991 4
1992 12
1993 6
1994 14
1995 8
1996 8
1997 15
1998 19
1999 23
2000 24
2001 15
2002 33
2003 29
2004 35
2005 37
2006 35
2007 50
2008 51
2009 43
2010 43
2011 50
2012 61
2013 42
2014 45
2015 44
2016 47
2017 32
2018 39
2019 12
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

809 results
Results by year
Filters applied: . Clear all
Page 1
Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
Sato M, et al. Clin Exp Nephrol 2018. PMID 28434126
Peripheral blood B-lymphocyte (B-cell) depletion is strongly correlated with persistent remission, relapse rarely occurring during B-cell depletion; however, we have encountered several such patients. METHODS: We retrospectively analyzed the characteristics and clinical course of 82 patients with SDNS treated with rituximab from January 2007 to December 2012 in our institution. ...
Peripheral blood B-lymphocyte (B-cell) depletion is strongly correlated with persistent remission, relapse rarely occurring du …
Lymphocyte depletion after alemtuzumab induction disrupts intestinal fungal microbiota in cynomolgus monkeys.
Li Q, et al. Transplantation 2014. PMID 25136848
This study aimed to define the biologic impact of lymphocyte depletion on gut fungal microbiota and their relationship. METHODS: Fifteen male cynomolgus monkeys with CD52 antigen negative on erythrocytes were administered intravenously with a single dose (3.0 mg kg body weight) of alemtuzumab. ...CONCLUSION: Our findings demonstrate that mucosal lymphocyte depletion leads to the dysbiosis of gut fungal microbiota, suggesting its role in maintaining host-fungus homeostasis. ...
This study aimed to define the biologic impact of lymphocyte depletion on gut fungal microbiota and their relationship. MET
Alemtuzumab depletion failure can occur in multiple sclerosis.
Dubuisson N, et al. Immunology 2018. PMID 29247512 Free PMC article.
At the population level there was lack of influence of 'ever-positive' alemtuzumab-specific antibody responses on lymphocyte depletion, clinical efficacy and adverse effects during the 2-year trial. ...However, at the individual level, NAbs led to poor lymphocyte depletion. Importantly, it was evident that 31% of people had NAbs and 75% had binding antibodies at the end of treatment-cycle 2, which suggests that problems may occur in people requiring additional alemtuzumab cycles. ...
At the population level there was lack of influence of 'ever-positive' alemtuzumab-specific antibody responses on lymphocyte deple
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
Li Z, et al. Clin Exp Immunol 2018 - Clinical Trial. PMID 30144037 Free PMC article.
Approximately 40 and 80% of patients had total lymphocyte counts, reaching the lower limit of normal by 6 and 12 months after each course, respectively. The clearance of alemtuzumab is dependent on circulating lymphocyte count. A majority of treated patients tested positive for anti-alemtuzumab antibodies, including inhibitory antibodies, during the 2-year studies, and a higher proportion of patients tested positive in course 2 than in course 1. ...
Approximately 40 and 80% of patients had total lymphocyte counts, reaching the lower limit of normal by 6 and 12 months after each co …
B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Pescovitz MD, et al. Diabetes Care 2014 - Clinical Trial. PMID 24026563 Free PMC article.
OBJECTIVE: We previously reported that selective depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody, slowed decline of β-cell function in recent-onset type 1 diabetes mellitus (T1DM) at 1 year. ...RESEARCH DESIGN AND METHODS: Eighty-seven subjects (aged 8-40 years) were randomly assigned to, and 81 received, infusions of rituximab or placebo on days 1, 8, 15, and 22. ...
OBJECTIVE: We previously reported that selective depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody, slowed …
In vivo depletion of CD4- and CD8-specific T cells.
Kruisbeek AM. Curr Protoc Immunol 2001. PMID 18432792
In vivo depletion of CD4- and CD8-specific T cells is a means of studying the role of these subpopulations in the initiation and effector phases of particular in vivo immune responses. ...Depletion of the appropriate subset of T cells is verified by flow cytometry analysis of lymph node and spleen cell suspensions in pilot experiments. ...
In vivo depletion of CD4- and CD8-specific T cells is a means of studying the role of these subpopulations in the initiation and effe …
809 results
Jump to page
Feedback